A potential development in the treatment of cancer has been achieved by researchers at the Indian Association for the Cultivation of Science (IACS) in Kolkata. They discovered that they may be able to assist individuals whose cancer has become resistant to existing treatments by focusing on TDP1, an enzyme involved in DNA repair. New combination therapy for cancer may result from this research.
Current Cancer Treatments Have No Effect On Another Set Of Cells
- Cancer therapies frequently inhibit the enzyme Topoisomerase 1 (Top1) that assists with DNA copying.
- Eventually, some of these cancer cells develop resistance to these drugs and diminish the effectiveness of currently used therapeutic approaches.
- TDP1 and Cyclin-dependent kinase 1 (CDK1) scientists are targeting for innovative cancer treatments.
- Top1 inhibitors cause TDP1 to repair this damage and promote survival of cancer cells.
- CDK1 is a cyclin dependent protein kinase associated with the cell cycle, and extensively involved in regulating cell division era.
- Inhibition of CDK1 gives TDP1 no chance to repair the DNA damage caused by Top1 inhibitors in cancer cells.
- Together: This combination therapy has the potential to enhance cancer treatment efficacy, be it in cases that are resistant.
- This treatment will be confirmed in animal studies before the development of precision medicine treatments.
- TDP1: a human, yeast and bacterial essential enzyme in DNA repair processes during DNA replication.
Month: Current Affairs - November 11, 2024
Category: